检索结果-南通市图书馆

Tislelizumab in previously treated,locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2024年第3期36卷 257-269页

作者： Jian Li Ye Xu Aimin Zang Yunong Gao Quanli Gao Yanqiao Zhang Dong Wang Jianming Xu Ying Yuan Haiping Jiang Jieer Ying Chunmei Shi Yanhong Deng Jing Wang Tianshu Liu Yi Huang xiaoping qian Yueyin Pan Ying Cheng Sheng Hu Jin Wang Mengyue Shi Ke Wang Han Hu Lin Shen State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers Beijing Key Laboratory of Carcinogenesis and Translational ResearchDepartment of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Oncology Fudan University Shanghai Cancer CenterShanghai 200032China Department of Medical Oncology Affiliated Hospital of Hebei UniversityBaoding 071000China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of GynecologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Immunotherapy Henan Cancer HospitalZhengzhou 450001China Department of Gastrointestinal Oncology Affiliated Cancer Hospital of Harbin Medical UniversityHarbin 150086China Department of Gastrointestinal Oncology Chongqing University Cancer HospitalChongqing 400030China Department of Gastrointestinal Oncology the Fifth Medical CenterChinese PLA General HospitalBeijing 100048China Department of Medical Oncology the Second Affiliated HospitalZhejiang University School of MedicineHangzhou 310009China Department of Medical Oncology the First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Medical Oncology Cancer Hospital of the University of Chinese Academy of SciencesHangzhou 310022China Department of Medical Oncology Fujian Medical University Union HospitalFuzhou 350001China Department of Oncology the Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhou 510655China Department of Medical Oncology Hunan Cancer HospitalChangsha 410013China Department of Medical Oncology Zhongshan HospitalFudan UniversityShanghai 200032China Department of Immunotherapy Hubei Cancer HospitalWuhan 430079China Department of Medical Oncology the Affiliated Hospital of Nanjing University Medical SchoolNanjing 210008China Department of Medical Oncology Anhui Provincial HospitalHefei 230001China Department of Medical Oncology Jilin Cancer Hospital

Objective:The open-label,phase II RATIONALE-209 study evaluated tislelizumab(anti-programmed cell death protein 1 antibody)as a tissue-agnostic monotherapy for microsatellite instability-high(MSI-H)/mismatch repair-deficient(dMMR)***:Adults with previously treated,locally advanced unresectable or metastatic MSI-H/dMMR solid tumors were *** received tislelizumab 200 mg intravenously every 3 *** response rate(ORR;primary endpoint),duration of response(DoR),and progression-free survival(PFS)were assessed by independent review committee(Response Evaluation Criteria in Solid Tumors v1.1).Results:Eighty patients were enrolled and treated;75(93.8%)patients had measurable disease at *** had metastatic disease and received at least one prior therapy for advanced/metastatic disease(n=79;98.8%).At primary analysis(data cutoff July 8,2021;median follow-up 15.2 months),overall ORR[46.7%;95%confidence interval(95%CI),35.1−58.6;one-sided P<0.0001]and ORR across tumor-specific subgroups[colorectal(n=46):39.1%(95%CI,25.1–54.6);gastric/gastroesophageal junction(n=9):55.6%(95%CI,21.2−86.3);others(n=20):60.0%(95%CI,36.1−80.9)]were significantly greater with tislelizumab vs.a prespecified historical control ORR of 10%;five(6.7%)patients had complete *** DoR,PFS,and overall survival were not reached with long-term follow-up(data cutoff December 5,2022;median follow-up 28.9 months).Tislelizumab was well tolerated with no unexpected safety ***-related adverse events(TRAEs)of grade≥3 occurred in 53.8%of patients;7.5%of patients discontinued treatment due to ***:Tislelizumab demonstrated a significant ORR improvement in patients with previously treated,locally advanced unresectable or metastatic MSI-H/dMMR tumors and was generally well tolerated.

关键词： Biomarkers DNA mismatch repair immune checkpoint inhibitors microsatellite instability phase II clinical trials programmed cell death 1 receptor

浙江省杭州市零售食品中小肠结肠炎耶尔森菌污染状况及药物敏感性特征分析

在线全文

学校读者我要写书评

暂无评论

疾病监测 2024年第8期39卷 1067-1073页

作者：吴月黄振洲钱小平肖骁张蔚楼秀芹李钧杭州市疾病预防控制中心(杭州市卫生监督所) 浙江杭州310021 富阳区疾病预防控制中心浙江杭州311400

目的了解浙江省杭州市零售食品中小肠结肠炎耶尔森菌的污染程度及其药物敏感性现状。方法收集2019年、2021年及2022年杭州市各区、县零售的不同种类食品,对小肠结肠炎耶尔森菌进行分离纯化鉴定和毒力基因检测,采用微量肉汤稀释法对分... 详细信息

目的了解浙江省杭州市零售食品中小肠结肠炎耶尔森菌的污染程度及其药物敏感性现状。方法收集2019年、2021年及2022年杭州市各区、县零售的不同种类食品,对小肠结肠炎耶尔森菌进行分离纯化鉴定和毒力基因检测,采用微量肉汤稀释法对分纯的菌株进行药物敏感性测定,分析其耐药特征及耐药谱。结果共采集到不同零售食品样本460份,134份分离鉴定出小肠结肠炎耶尔森菌,检出率为29.13%,其中禽肉及其制品检出率为41.00%,畜肉及其制品检出率为37.43%。所有菌株均缺失ystA、ail、virF和yadA毒力基因,但131株菌(97.76%)携带ystB基因。药敏分析结果显示,分离株对14种抗生素有不同程度的耐药,其中对头孢唑林耐药率最高(98.51%),其次是氨苄西林(45.52%)、萘啶酸(23.88%)和头孢西丁(12.69%),对其他10种抗生素耐药率为0.75%~5.00%,其中发现2株分离株对多黏菌素B耐药。多重耐药菌占23.88%,其中4重及以上耐药菌占9.70%,耐药谱分散,无明显聚集现象,最高可耐受7种抗生素(1株)。组内分析发现,2022年的菌株对氨苄西林及头孢西丁的敏感率显著高于2021年。结论杭州市零售食品中小肠结肠炎耶尔森菌污染率较高,尤其是禽畜肉制品,分离株均为非致病性的,ystB基因携带率高;小肠结肠炎耶尔森菌对多黏菌素出现耐药,需加强对各类食品中小肠结肠炎耶尔森菌及其耐药特征的监测。

关键词：小肠结肠炎耶尔森菌零售食品污染情况药物敏感性多黏菌素B

同方期刊数据库

How to Develop into An International Metropolis in the Context of the Silk Road Economic Belt —— A Case Study of Xi'an

在线全文

学校读者我要写书评

暂无评论

学术界 2015年第4期 318-322页

作者： Chen Weifeng qian xiaoping Business College Xi'an University

For Xi'an,the central city of the Silk Road Economic Belt,it is both the theoretical and practical problem to develop into an international metropolis,so how to develop into an international metropolis becomes the research focus. This paper firstly introduces the necessity,the current situation and the evaluation index system of the construction of the city Xi'an in the context of the Silk Road Economic Belt; then it analyzes the econom ic developm ent of the three old districts,the three new districts,the three suburban districts and the four counties; and finally it puts forward the development path for Xi'an in the context of the Silk Road Economic Belt — the development pattern of "five districts,one international harbor area and two bases""nine-grid-pattern "economic development and the function-oriented coordinated development of the regional economy.

关键词：国际化大都市丝绸之路经济带西安语境评价指标体系中心城市经济发展

HER2阳性转移性结直肠癌靶向治疗研究进展

在线全文

学校读者我要写书评

暂无评论

肿瘤预防与治疗 2024年第7期37卷 618-623页

作者：李雨晴胡静钱晓萍东南大学医学院南京鼓楼医院南京210008 南京大学医学院附属鼓楼医院肿瘤中心南京210008

结直肠癌是全球最常见的恶性肿瘤之一,尤其转移性结直肠癌(metastatic colorectal cancer,mCRC)预后较差。人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)作为mCRC新兴的生物标志物近年来备受瞩目,本文就HER2阳性... 详细信息

结直肠癌是全球最常见的恶性肿瘤之一,尤其转移性结直肠癌(metastatic colorectal cancer,mCRC)预后较差。人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)作为mCRC新兴的生物标志物近年来备受瞩目,本文就HER2阳性mCRC靶向治疗研究进展做一综述,为结直肠癌的诊断、治疗及预后提供参考。

关键词：人表皮生长因子受体2 转移性结直肠癌靶向治疗生物标志物

“放-靶-免”组合在微卫星稳定型晚期结直肠癌三线治疗中的价值初步探索

在线全文

学校读者我要写书评

暂无评论

现代肿瘤医学 2024年第10期32卷 1843-1847页

作者：章群胡静钱晓萍李丽南京大学医学院附属南京鼓楼医院肿瘤中心江苏南京210008

目的:探讨“放-靶-免”联合治疗模式在微卫星稳定型(MSS)晚期结直肠癌患者三线治疗中的临床价值及毒副反应评估。方法:回顾性分析我院肿瘤中心接受上述联合治疗模式的MSS亚型晚期结直肠癌患者,对其治疗疗效及毒副反应进行评估。结果:5... 详细信息

目的:探讨“放-靶-免”联合治疗模式在微卫星稳定型(MSS)晚期结直肠癌患者三线治疗中的临床价值及毒副反应评估。方法:回顾性分析我院肿瘤中心接受上述联合治疗模式的MSS亚型晚期结直肠癌患者,对其治疗疗效及毒副反应进行评估。结果:5例接受“放-靶-免”联合治疗模式的MSS亚型晚期结直肠癌患者中最佳疗效评价为部分缓解的1例,疾病稳定的2例,疾病进展的2例,疾病控制率(DCR)为60.0%(3/5)。而在毒副反应方面,5例患者均未出现III-IV级毒副反应。结论:“放-靶-免”组合模式有望为难治性的MSS亚型的晚期结直肠癌三线治疗提供新的策略,当然该结论仍需要更大的样本量进行验证。

关键词：晚期结直肠癌联合治疗微卫星稳定放疗靶向治疗免疫治疗

三药化疗在局部进展期直肠癌新辅助治疗中的应用

在线全文

学校读者我要写书评

暂无评论

山东第一医科大学（山东省医学科学院）学报 2024年第9期45卷 573-576页

作者：李雨晴胡静钱晓萍东南大学医学院江苏南京210009 南京大学医学院附属鼓楼医院肿瘤中心江苏南京210008

目前局部进展期直肠癌(locally advanced rectal cancer,LARC)的标准治疗模式为新辅助放化疗联合直肠全系膜切除和辅助化疗,患者的生存预后显著改善,但远处转移率仍较高。既往常应用于新辅助治疗中的化疗方案为FOLFOX(奥沙利铂+氟尿嘧啶... 详细信息

目前局部进展期直肠癌(locally advanced rectal cancer,LARC)的标准治疗模式为新辅助放化疗联合直肠全系膜切除和辅助化疗,患者的生存预后显著改善,但远处转移率仍较高。既往常应用于新辅助治疗中的化疗方案为FOLFOX(奥沙利铂+氟尿嘧啶/亚叶酸钙)或FOLFIRI(伊立替康+氟尿嘧啶/亚叶酸钙)双药方案,而FOLFOXIRI(氟尿嘧啶/亚叶酸钙+奥沙利铂+伊立替康)三药方案强度更高,本文就三药化疗在LARC新辅助治疗中的应用展开综述,以期为临床诊疗提供参考。

关键词：三药化疗局部进展期直肠癌新辅助治疗

刍议Excel在一体化住院药房盘点中的应用

在线全文

学校读者我要写书评

暂无评论

中国卫生产业 2024年第9期21卷 143-147页

作者：金涛王彩云钱晓萍南京大学医学院附属苏州医院药学部江苏苏州215153

住院药房一体化是将住院药房与静脉用药调配中心(Pharmacy Intravenous Admixture Services,PIVAs)统一的管理模式。常规的一体化住院药房的盘点为线性流程,通常需要在药房系统停止发药后进行静态盘点,但在盘点时存在一个药品多位存储... 详细信息

住院药房一体化是将住院药房与静脉用药调配中心(Pharmacy Intravenous Admixture Services,PIVAs)统一的管理模式。常规的一体化住院药房的盘点为线性流程,通常需要在药房系统停止发药后进行静态盘点,但在盘点时存在一个药品多位存储、数据需要手动计算、盘点误差率较高等缺点。南京大学医学院附属苏州医院根据一体化药房工作流程的特点,通过优化盘点中的流程,灵活使用Excel函数及VBA功能,降低药房人工成本,提高工作效率,并减少手动运算误差。

关键词： Excel 一体化住院药房药品盘点

Analysis on the types of chemokines expressed by the murine thymic epithelial cell line MTEC1

维普期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

Chinese Science Bulletin 2000年第12期45卷 1098-1101页

作者： Laiping Xie xiaoping qian Sunyou Gong Weifeng Chen Beijing Med Univ Dept Immunol Beijing 100083 Peoples R China

Six kinds of chemokines including SDF-1α, IP-10, KG, RANTES, MCP-1 and Lymphotactin have been amplified using the primers designed by ourselves with RT-PCR from the total RNA of a medullary-type murine thymic epithelial cell line MTEC1 cells. The amplified cDNA fragments of the chemokines have been identified by nucleotide sequencing and Northern blot analysis. The results demonstrate that there are two different splicing forms of SDF-1 mRNA existing in MTEC1. The concentrated culture supernatant of MTEC1 shows an intermediate level of chemotaxis to CD4-CD8- thymocytes, which conforms to the biological function of SDF-1.

关键词： thymic epithelial cells chemokines analysis.

Functional maturation of two murine medullary-type CD8SP thymocytes

在线全文

学校读者我要写书评

暂无评论

Chinese Science Bulletin 2001年第9期46卷 746-751页

作者： Tian Tian qian xiaoping Gao Ling Chen Weifeng Department of Immunology Bejing Medical UniversityBejing 100083China

TCRαβTCD4-CD8+ thymocytes are heterogeneity. They may undergo phenotypic and functional maturation within thymic medulla. Medullary-type CD8SP thymocytes were divided into seven subsets based on phenotypic analysis, and their precursor-progeny relationship along with the differential pathway was also delineated. To further testify the validity of the maturation pathway, we purified 6C10-CD69+ cells representing the early stage and 6C10-Qa-2+ cells representing the later stage among medullary-type CD8SP thymocytes and compared their functional maturation levels. CD8+ T cells of spleen were used as the control. It is shown that there is no obvious difference of proliferation ability among these three subsets; however, intracytoplasmic cytokine assay shows that there is a hierarchy of IFN-γ and TNFα secretion among these subsets, strikingly comparable to their phenotypic status among medullary type CD8SP thymocytes. The bioassays of IL-2 and IFN-γ in culture supernatant give the similar results.

关键词： CD4^(-)CD8^(+)thymocyte phenotype function